Proxima, Laserscope, Medtronic Qualify For Improved Outpatient Payments
This article was originally published in The Gray Sheet
Executive Summary
Adoption of Proxima Therapeutics' MammoSite high-dose rate brachytherapy catheter for early-stage breast cancer will increase with its placement into a new-technology APC, the firm maintains
You may also be interested in...
American Medical Buys Laserscope For GreenLight Obstructive BPH Treatment
American Medical Systems will expand its benign prostatic hyperplasia treatment offerings to include operating room-based obstructive BPH therapy with Laserscope's GreenLight surgical laser system under a June 5 acquisition agreement
American Medical Buys Laserscope For GreenLight Obstructive BPH Treatment
American Medical Systems will expand its benign prostatic hyperplasia treatment offerings to include operating room-based obstructive BPH therapy with Laserscope's GreenLight surgical laser system under a June 5 acquisition agreement
Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry
Cytyc likely will divest Proxima Therapeutics' GliaSite brain tumor radiation therapy system after acquiring the company for its MammoSite breast cancer system under a $160 mil. deal Feb. 9